Production (Stage)
Inovio Pharmaceuticals, Inc.
INO
$2.22
-$0.05-2.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.36% | 22.48% | 25.83% | 9.28% | 25.04% |
| Total Depreciation and Amortization | -2.13% | 342.81% | -25.84% | -27.53% | -34.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -274.80% | -149.27% | -101.65% | -67.08% | 32.94% |
| Change in Net Operating Assets | -460.79% | 65.37% | 61.26% | 179.17% | -157.61% |
| Cash from Operations | 6.56% | 25.16% | 5.73% | 12.70% | 21.56% |
| Capital Expenditure | -66.85% | -- | -- | -1,792.47% | 88.01% |
| Sale of Property, Plant, and Equipment | -- | -60.01% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -99.98% | 74.72% | 356.25% | -80.68% | 243.40% |
| Cash from Investing | -100.11% | 73.71% | 356.25% | -81.51% | 138.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.91% | 611.61% | -5.82% | 487.52% | -- |
| Repurchase of Common Stock | 57.41% | -- | 34.02% | -643.34% | 58.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 109.05% | 1,485.45% | -5.44% | 1,045.85% | -2,575.79% |
| Foreign Exchange rate Adjustments | -- | -100.00% | 100.00% | 100.00% | 1,805.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -589.47% | 1,081.95% | 62.53% | -39.57% | 129.25% |